Previous 10 | Next 10 |
AnaptysBio ([[ANAB]] +12.6%) had its price target lifted by Truist from $16 to $20, and keeps a Buy rating on the stockThe analyst cites the company's positive imsidolimab data from generalized pustular psoriasis study, with 6 out 8 treated patients showed improvement on CGI scale - the ...
Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers:...
Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...
AnaptysBio ([[ANAB]] +4.4%) has announced interim data (from 8 patients enrolled) from GALLOP Phase 2 trial evaluating imsidolimab for the treatment of generalized pustular psoriasis ((GPP)), a very rare form of psoriasis characterized by pus-filled blisters on the skin.6 ...
6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29, with rapid reduction of skin pustules by 60% on Day 8 and 94% clearance on Day 29 FDA end-of-Phase 2 meeting anticipated in Q4 2020 to outline registration path of imsid...
SAN DIEGO, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of&...
Shuman Glenn & Stecker announces that it is investigating potential shareholder claims against certain officers and directors of AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (Nasdaq: ANAB ). AnaptysBio is a clinical stage biotechnology company. The F...
Seres Therapeutics stock jumps on positive topline data Seres Therapeutics Inc. ( MCRB ) stock recorded swift boost as the company announced positive data from its Phase 3 ECOSPOR III study. The company reported that the drug candidate was able to bring about statistically significant ch...
Thinly traded micro cap AnaptysBio ( ANAB -5.2% ) is down, albeit on modest turnover of 42K shares, in reaction to preliminary results from a Phase 2 clinical, ECLIPSE , evaluating lead candidate etokimab in patients with chronic rhinosinusitis with nasal polyps. More news on: Anaptys...
AnaptysBio (NASDAQ: ANAB ) : Q2 GAAP EPS of -$0.79 misses by $0.04 . More news on: AnaptysBio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...